Cancer Immunotherapy

OK-432 Stimulates Immune Responses From Lymph Node Cells of Cancer Patients

Published in Cancer Weekly, November 9th, 1998

OK-432 stimulates cytotoxic T lymphocyte (CTL) and lymphokine-activated killer (LAK) cell activity in mononuclear cells from the regional lymph nodes of lung cancer patients.

K. Takahashi and colleagues from the University of Tokushima, Japan, examined the effect of OK-432 on the induction of CTLs directed against autologous tumor cells (ATC) and LAK cells from the mononuclear cells separated from regional lymph node cells (RLMNCs) of lung cancer patients. Samples were tested from forty-nine patients ("OK-432 Develops CTL and LAK Activity in Mononuclear Cells from Regional Lymph Nodes of Lung Cancer Patients," International Journal of Immunopharmacology, August...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-11-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry